查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930021

白蛋白市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2025-2034）

Albumin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 160 Pages | 商品交期: 請詢問到貨日

價格

白蛋白市場成長驅動因子

2025年，全球白蛋白市場呈現強勁成長，達72.3億美元。白蛋白是一種在肝臟合成的關鍵血漿蛋白，在維持滲透壓、運輸激素和營養物質以及支持重要的治療應用方面發揮著非常重要的作用。預計到2026年，市場規模將成長至77億美元，到2034年將達到133.3億美元，在整個預測期內保持穩定成長。北美在2025年佔據了21.71%的領先市場佔有率，這主要得益於強勁的治療需求、先進的血漿採集基礎設施以及活躍的醫藥投資活動。

白蛋白產品廣泛應用於低白蛋白血症治療、藥物傳遞系統、傷口照護、肝病及重症監護等領域。 住院率上升、慢性肝病、心臟手術以及感染率的增加顯著推動了臨床需求。持續的研究和不斷擴大的治療適應症增強了白蛋白市場的長期成長前景。

市場驅動因素與成長因素

白蛋白市場成長的關鍵驅動因素之一是低白蛋白血症和肝臟相關疾病的盛行率不斷上升。敗血症、肝硬化、腎臟病和心血管手術等疾病通常會導致白蛋白合成減少，需要進行白蛋白治療。根據本報告引用的肝病盛行率資料，光在美國就有相當數量的患者需要接受白蛋白輸注作為標準重症監護方案的一部分。

此外，全球人口老化持續加重疾病負擔，尤其是在更容易出現白蛋白缺乏的老年患者。生物製藥產業的成長也是主要驅動力之一，白蛋白日益被用作生物製劑、免疫療法和單株抗體開發中的穩定劑和載體蛋白。不斷上漲的醫療保健成本和不斷擴大的臨床研究活動進一步推動了市場擴張。

市場限制與監理挑戰

儘管需求趨勢良好，但白蛋白市場面臨著與血漿採集、加工和商業化相關的嚴格監管限制。在美國和加拿大等地區，白蛋白生產受到嚴格的血液安全法律監管，要求符合品質、捐贈者安全和可追溯性標準。審批時間長和符合標準的血漿來源有限增加了營運複雜性，並可能阻礙某些國家市場的快速滲透。

新機會與市場趨勢

重組白蛋白產品研發投入的增加正湧現出巨大的市場機會。 重組白蛋白具有純度高、污染風險低、適用於藥物遞送及先進療法等優點。本報告重點介紹了人們對無血重組產品的日益成長的興趣，這些產品能夠提高患者安全性並實現規模化生產。

主要製造商之間的策略聯盟和合作夥伴關係加速創新。 Grifols S.A.、CSL Behring 和Takeda Pharmaceutical Company Limited等公司正積極透過臨床試驗、地域擴張和監管審批來擴展其白蛋白產品組合。白蛋白在藥物遞送系統和個人化醫療中的應用日益廣泛，這將繼續成為影響市場需求的關鍵趨勢。

依細分市場分析

依產品類型劃分，人血清白蛋白將在2026年佔據市場主導地位，市場佔有率將達到89.66%，這主要得益於政府的批准和較高的臨床應用率。重組白蛋白因其在生物製劑和先進療法中的應用而持續受到關注，而牛血清白蛋白在研究應用方面保持著穩定的需求。

依應用領域劃分，治療領域將引領市場，在2026年佔據65.17%的市場佔有率，這主要得益於醫院和重症監護室處方量的增加。診斷和研究應用領域也呈現穩定成長，這得益於慢性病篩檢的增加和檢測基礎設施的擴展。

區域展望

亞太地區白蛋白市場預計在2025年達到40.1億美元，2026年達到43.3億美元，成為最大的區域市場。成長主要得益於中國、日本和印度私立醫院基礎設施的擴張以及血漿衍生療法的日益普及。北美市場預計在2026年達到16.6億美元，主要得益於較高的治療用途和積極的研發活動。歐洲市場預計在2026年達到10.8億美元，這主要得益於血漿分離技術的擴展和監管政策的改善。

這份全球白蛋白市場報告對2025年至2034年的產業格局進行了全面評估，其中2025年為基準年，2026年和2034年為市場規模預測的關鍵參考年份。報告詳細分析了市場規模和價值趨勢、成長因素以及主要地區的競爭格局。

本研究依產品類型、應用和最終用戶進行了詳細分析，重點介紹了人類血清白蛋白、重組白蛋白和牛血清白蛋白在治療、診斷和研究應用中的表現。報告涵蓋北美、歐洲、亞太、拉丁美洲以及中東和非洲地區，並對包括美國、中國、日本、德國和英國在內的主要市場進行了詳細的國別分析。

此外，報告還評估了市場驅動因素、限制因素、機會、挑戰和新興趨勢，以及監管框架和技術進步的影響。 競爭格局部分概述了主要行業參與者，並分析了影響全球白蛋白市場的策略趨勢，包括合作關係、產品發布、產能擴張和監管批准。

低白蛋白血症、肝病和嚴重疾病的盛行率不斷上升，以及白蛋白在生物製劑和藥物遞送系統中的應用日益廣泛，推動了市場成長。儘管監管的複雜性和高昂的生產成本構成了挑戰，但對重組技術的持續投資、血漿基礎設施的擴大以及戰略聯盟鞏固市場的基礎。

依地區劃分，亞太地區持續引領成長，其次是北美和歐洲。這主要歸功於醫療保健基礎設施的不斷改進、血漿衍生療法的日益普及以及強勁的研發活動。總體而言，在臨床需求、技術創新以及與先進治療應用日益融合的推動下，白蛋白市場預計將經歷長期的穩定成長。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 關鍵考慮因素

  • 2024/2025年主要國家和地區主要疾病流行情況
  • rHSA產品參數概述
  • 主要公司新產品發布
  • 主要公司產品線分析
  • 主要產業趨勢（併購與合作）
  • COVID-19疫情的影響市場

第5章 全球白蛋白市場分析、洞察與預測（2021-2034）

  • 市場分析、洞察與預測 - 依產品分類
    • 人血清白蛋白
    • 重組白蛋白
    • 牛血清白蛋白
  • 市場分析、洞察與預測 - 依應用分類
    • 治療
    • 診斷
    • 研究
  • 市場分析、洞察與預測 - 依最終用戶分類
    • 醫院和診所
    • 製藥和生物技術產業
    • 研究機構
  • 市場分析、洞察與預測 - 依地區分類
    • 北方美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美白蛋白市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲白蛋白市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞半島
    • 歐洲其他地區

第8章 亞太地區白蛋白市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 亞太其他地區

第9章 拉丁美洲白蛋白市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第10章 中東與非洲白蛋白市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • GCC國家
    • 南非
    • 中東其他地區非洲

第11章 競爭分析

  • 全球市佔率分析（2025年）
  • 公司簡介
    • CSL Behring（CSL）
    • Kedrion S.p.A.
    • Takeda Pharmaceutical Company Limited
    • Lazuline Bio
    • InVitria
    • Biorbyt Ltd.
    • Grifols, S.A.
    • Octapharma AG
    • Albumin Bioscience
    • Aspira Chemical
    • ALBUMEDIX（Sartorius AG）
    • Cyagen Biosciences
    • Merck KGaA
    • Thermo Fisher Scientific Inc.
Product Code: FBI102637

Growth Factors of albumin Market

The global albumin market demonstrated strong momentum in 2025, with the market valued at USD 7.23 billion. Albumin, a vital plasma protein synthesized by the liver, plays a crucial role in maintaining oncotic pressure, transporting hormones and nutrients, and supporting critical therapeutic applications. The market is projected to expand to USD 7.70 billion in 2026 and further reach USD 13.33 billion by 2034, reflecting consistent expansion during the forecast period. In 2025, North America held a leading position with a 21.71% market share, supported by robust therapeutic demand, advanced plasma collection infrastructure, and strong pharmaceutical investment activity.

Albumin products are extensively used in hypoalbuminemia treatment, drug delivery systems, wound care, liver disorders, and critical care settings. Rising hospitalization rates, increasing prevalence of chronic liver diseases, cardiac surgeries, and infectious conditions have significantly elevated clinical demand. Continuous research activity and expanding therapeutic indications are reinforcing the long-term growth outlook of the albumin market.

Market Drivers and Growth Factors

One of the primary drivers of albumin market growth is the increasing prevalence of hypoalbuminemia and liver-related disorders. Conditions such as sepsis, cirrhosis, renal disorders, and cardiovascular surgeries frequently result in reduced albumin synthesis, necessitating albumin-based therapies. According to liver disease prevalence data cited in the report, a substantial patient population in the U.S. alone requires albumin infusion as part of standard critical care protocols.

Additionally, the aging global population continues to contribute to rising disease burden, especially among elderly patients who are more susceptible to albumin deficiency. Growth of the biopharmaceutical industry is another major catalyst, as albumin is increasingly used as a stabilizing agent and carrier protein in biologics, immunotherapy, and monoclonal antibody development. Rising healthcare expenditure and expanding clinical research activities further support market expansion.

Market Restraints and Regulatory Challenges

Despite favorable demand dynamics, the albumin market faces constraints related to stringent regulatory frameworks governing plasma collection, processing, and commercialization. In regions such as the U.S. and Canada, albumin production is regulated under strict blood safety laws, requiring compliance with quality, donor safety, and traceability standards. Lengthy approval timelines and limited availability of compliant plasma sources increase operational complexity and may restrict rapid market penetration in certain countries.

Emerging Opportunities and Market Trends

Significant market opportunities are emerging from increased R&D investments in recombinant albumin products. Recombinant albumin offers advantages such as high purity, reduced contamination risk, and suitability for drug delivery and advanced therapies. The report highlights growing interest in blood-free recombinant formulations, which enhance patient safety and enable scalable production.

Strategic collaborations and partnerships among leading manufacturers are accelerating innovation. Companies such as Grifols S.A., CSL Behring, and Takeda Pharmaceutical Company Limited are actively expanding their albumin portfolios through clinical trials, geographic expansion, and regulatory approvals. Increased adoption of albumin in drug delivery systems and personalized medicine remains a key trend shaping future demand.

Segmentation Insights

By product type, human serum albumin dominated the market, accounting for 89.66% share in 2026, driven by government approvals and high clinical adoption. Recombinant albumin continues to gain traction due to its application in biologics and advanced therapies, while bovine serum albumin maintains steady demand in research applications.

From an application perspective, the therapeutics segment led the market, holding 65.17% share in 2026, supported by increasing prescriptions in hospitals and critical care units. Diagnostics and research applications also exhibited steady growth due to rising chronic disease screening and expanding laboratory infrastructure.

Regional Outlook

The Asia Pacific albumin market generated USD 4.01 billion in 2025, rising to USD 4.33 billion in 2026, making it the largest regional market. Growth is supported by expanding private hospital infrastructure and increased adoption of plasma-derived therapies in China, Japan, and India. North America followed with a market size of USD 1.66 billion in 2026, driven by high therapeutic usage and strong R&D activity. Europe reached USD 1.08 billion in 2026, supported by plasma fractionation expansion and regulatory advancements.

Competitive Landscape

The competitive landscape is characterized by product launches, facility expansions, and strategic partnerships. Key players continue to strengthen their global presence through innovation and regulatory approvals, ensuring sustained market competitiveness across regions.

Report Coverage

The global albumin market report delivers a comprehensive assessment of the industry landscape for the period 2025 to 2034, with 2025 as the base year and 2026 and 2034 as key reference years for market sizing and forecasting. The report provides in-depth insights into market size and value trends, growth dynamics, and competitive positioning across major regions.

The study covers detailed analysis by product type, application, and end user, highlighting the performance of human serum albumin, recombinant albumin, and bovine serum albumin across therapeutic, diagnostic, and research applications. Regional coverage includes North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with country-level insights for key markets such as the United States, China, Japan, Germany, and the United Kingdom.

In addition, the report evaluates market drivers, restraints, opportunities, challenges, and emerging trends, along with the impact of regulatory frameworks and technological advancements. The competitive landscape section profiles major industry participants and examines strategic developments such as partnerships, product launches, capacity expansions, and regulatory approvals that are shaping the global albumin market.

Conclusion

The global albumin market showed solid performance in 2025, with a market value of USD 7.23 billion, reflecting strong demand from therapeutic and biopharmaceutical applications. Continued expansion to USD 7.70 billion in 2026 and further growth to USD 13.33 billion by 2034 indicate sustained adoption of albumin-based products across clinical and research settings.

Growth momentum is supported by the rising prevalence of hypoalbuminemia, liver disorders, and critical care conditions, along with increasing use of albumin in biologics and drug delivery systems. While regulatory complexities and high production costs pose challenges, ongoing investments in recombinant technologies, plasma infrastructure expansion, and strategic collaborations are strengthening market fundamentals.

Regional growth remains led by Asia Pacific, followed by North America and Europe, driven by expanding healthcare infrastructure, rising plasma-derived therapy adoption, and strong R&D activity. Overall, the albumin market is positioned for steady long-term expansion, supported by clinical necessity, technological innovation, and increasing integration into advanced therapeutic applications.

Segmentation By Product

  • Human Serum Albumin
  • Recombinant Albumin
  • Bovine Serum Albumin

By Application

  • Therapeutics
  • Diagnostics
  • Research

By End-user

  • Hospital & Clinics
  • Pharmaceutical & Biotechnology Industry
  • Research Institutes

By Region

  • North America (By Product, Application, End-user, and Country)
    • U.S.
    • Canada
  • Europe (By Product, Application, End-user, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Application, End-user, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Application, End-user, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Application, End-user, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Disorders: by Key Countries/Sub-regions, 2024/2025
  • 4.2. Overview: rHSA Product Parameters
  • 4.3. New Product Launches, By Key Players
  • 4.4. Pipeline Analysis, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions and Partnerships)
  • 4.6. Impact of COVID-19 on the Market

5. Global Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Human Serum Albumin
    • 5.1.2. Recombinant Albumin
    • 5.1.3. Bovine Serum Albumin
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Therapeutics
    • 5.2.2. Diagnostics
    • 5.2.3. Research
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospital & Clinics
    • 5.3.2. Pharmaceutical & Biotechnology Industry
    • 5.3.3. Research Institutes
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Human Serum Albumin
    • 6.1.2. Recombinant Albumin
    • 6.1.3. Bovine Serum Albumin
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Therapeutics
    • 6.2.2. Diagnostics
    • 6.2.3. Research
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospital & Clinics
    • 6.3.2. Pharmaceutical & Biotechnology Industry
    • 6.3.3. Research Institutes
  • 6.4. Market Analysis - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Human Serum Albumin
    • 7.1.2. Recombinant Albumin
    • 7.1.3. Bovine Serum Albumin
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Therapeutics
    • 7.2.2. Diagnostics
    • 7.2.3. Research
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospital & Clinics
    • 7.3.2. Pharmaceutical & Biotechnology Industry
    • 7.3.3. Research Institutes
  • 7.4. Market Analysis, Insights and Forecast- By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Human Serum Albumin
    • 8.1.2. Recombinant Albumin
    • 8.1.3. Bovine Serum Albumin
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Therapeutics
    • 8.2.2. Diagnostics
    • 8.2.3. Research
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospital & Clinics
    • 8.3.2. Pharmaceutical & Biotechnology Industry
    • 8.3.3. Research Institutes
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Human Serum Albumin
    • 9.1.2. Recombinant Albumin
    • 9.1.3. Bovine Serum Albumin
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Therapeutics
    • 9.2.2. Diagnostics
    • 9.2.3. Research
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospital & Clinics
    • 9.3.2. Pharmaceutical & Biotechnology Industry
    • 9.3.3. Research Institutes
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Human Serum Albumin
    • 10.1.2. Recombinant Albumin
    • 10.1.3. Bovine Serum Albumin
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Therapeutics
    • 10.2.2. Diagnostics
    • 10.2.3. Research
  • 10.3. Market Analysis, Insights and Forecast - By End-user
    • 10.3.1. Hospital & Clinics
    • 10.3.2. Pharmaceutical & Biotechnology Industry
    • 10.3.3. Research Institutes
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC Countries
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. CSL Behring (CSL)
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Kedrion S.p.A.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Takeda Pharmaceutical Company Limited
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Lazuline Bio
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. InVitria
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Biorbyt Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Grifols, S.A.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Octapharma AG
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Albumin Bioscience
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Aspira Chemical
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. ALBUMEDIX (Sartorius AG)
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)
    • 11.2.12. Cyagen Biosciences
      • 11.2.12.1. Overview
      • 11.2.12.2. Products
      • 11.2.12.3. SWOT Analysis
      • 11.2.12.4. Recent Developments
      • 11.2.12.5. Strategies
      • 11.2.12.6. Financials (Based on Availability)
    • 11.2.13. Merck KGaA
      • 11.2.13.1. Overview
      • 11.2.13.2. Products
      • 11.2.13.3. SWOT Analysis
      • 11.2.13.4. Recent Developments
      • 11.2.13.5. Strategies
      • 11.2.13.6. Financials (Based on Availability)
    • 11.2.14. Thermo Fisher Scientific Inc.
      • 11.2.14.1. Overview
      • 11.2.14.2. Products
      • 11.2.14.3. SWOT Analysis
      • 11.2.14.4. Recent Developments
      • 11.2.14.5. Strategies
      • 11.2.14.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Albumin Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 2: Global Albumin Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 3: Global Albumin Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 4: Global Albumin Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Albumin Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 6: North America Albumin Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 7: North America Albumin Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 8: North America Albumin Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Albumin Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 10: Europe Albumin Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 11: Europe Albumin Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 12: Europe Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Albumin Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 14: Asia Pacific Albumin Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 15: Asia Pacific Albumin Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 16: Asia Pacific Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Albumin Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 18: Latin America Albumin Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 19: Latin America Albumin Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 20: Latin America Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Albumin Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 22: Middle East & Africa Albumin Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 23: Middle East & Africa Albumin Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 24: Middle East & Africa Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Albumin Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
  • Figure 2: Global Albumin Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Albumin Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Albumin Market Value Share (%), by End-user, 2025 & 2034
  • Figure 5: Global Albumin Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Albumin Market Value (USD billion), by Product, 2025 & 2034
  • Figure 7: North America Albumin Market Value Share (%), by Product, 2025
  • Figure 8: North America Albumin Market Value (USD billion), by Application, 2025 & 2034
  • Figure 9: North America Albumin Market Value Share (%), by Application, 2025
  • Figure 10: North America Albumin Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 11: North America Albumin Market Value Share (%), by End-user, 2025
  • Figure 12: North America Albumin Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Albumin Market Value Share (%), By Country, 2025
  • Figure 14: Europe Albumin Market Value (USD billion), by Product, 2025 & 2034
  • Figure 15: Europe Albumin Market Value Share (%), by Product, 2025
  • Figure 16: Europe Albumin Market Value (USD billion), by Application, 2025 & 2034
  • Figure 17: Europe Albumin Market Value Share (%), by Application, 2025
  • Figure 18: Europe Albumin Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 19: Europe Albumin Market Value Share (%), by End-user, 2025
  • Figure 20: Europe Albumin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Albumin Market Value (USD billion), by Product, 2025 & 2034
  • Figure 23: Asia Pacific Albumin Market Value Share (%), by Product, 2025
  • Figure 24: Asia Pacific Albumin Market Value (USD billion), by Application, 2025 & 2034
  • Figure 25: Asia Pacific Albumin Market Value Share (%), by Application, 2025
  • Figure 26: Asia Pacific Albumin Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 27: Asia Pacific Albumin Market Value Share (%), by End-user, 2025
  • Figure 28: Asia Pacific Albumin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Albumin Market Value (USD billion), by Product, 2025 & 2034
  • Figure 31: Latin America Albumin Market Value Share (%), by Product, 2025
  • Figure 32: Latin America Albumin Market Value (USD billion), by Application, 2025 & 2034
  • Figure 33: Latin America Albumin Market Value Share (%), by Application, 2025
  • Figure 34: Latin America Albumin Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 35: Latin America Albumin Market Value Share (%), by End-user, 2025
  • Figure 36: Latin America Albumin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Albumin Market Value (USD billion), by Product, 2025 & 2034
  • Figure 39: Middle East & Africa Albumin Market Value Share (%), by Product, 2025
  • Figure 40: Middle East & Africa Albumin Market Value (USD billion), by Application, 2025 & 2034
  • Figure 41: Middle East & Africa Albumin Market Value Share (%), by Application, 2025
  • Figure 42: Middle East & Africa Albumin Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 43: Middle East & Africa Albumin Market Value Share (%), by End-user, 2025
  • Figure 44: Middle East & Africa Albumin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Albumin Market Share (%), By Company, 2025